- mail us help@24marketresearch.com
- Int'l 1(332) 2424 294 (Int'l)
TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
The Asia Pacific 7-ADCA market size was valued at US$ 178.9 million in 2024 and is projected to reach US$ 232.6 million by 2030, at a CAGR of 4.5% during the forecast period 2024-2030.
7-ADCA (7-Aminodesacetoxycephalosporanic acid) is a key intermediate in the production of cephalosporin antibiotics, widely used in the pharmaceutical industry for treating various bacterial infections.
The Asia Pacific 7-ADCA market is experiencing moderate growth, driven by the region's expanding pharmaceutical sector and increasing demand for antibiotics. China dominates with a 55% market share, followed by India at 30% and Japan at 10%. In 2023, cephalosporin production accounted for 90% of 7-ADCA consumption, with research and development at 8%. The market saw a 6% increase in demand due to the development of new cephalosporin derivatives. Key players include North China Pharmaceutical Group (China) and Sandoz (Switzerland), collectively holding a 60% market share in the region. The industry is investing in fermentation technologies, with a 12% increase in R&D spending on enzymatic processes for 7-ADCA production in 2023. Challenges include regulatory pressures on antibiotic use and competition from other antibiotic classes, leading to a 5% focus on developing high-potency cephalosporins. The trend towards outsourced pharmaceutical manufacturing has driven an 8% growth in 7-ADCA demand from contract manufacturing organizations. The market is benefiting from increasing healthcare access in emerging economies, with a 10% rise in antibiotic consumption in countries like Indonesia and Vietnam.
Report Includes
This report is an essential reference for who looks for detailed information on Asia Pacific 7-ADCA . The report covers data on Asia Pacific markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Asia Pacific major vendors¡¯ information. In addition to the data part, the report also provides overview of 7-ADCA , including classification, application, manufacturing technology, industry chain analysis and latest market dynamics. Finally, a customization report in order to meet user's requirements is also available.
This report aims to provide a comprehensive presentation of the Asia Pacific 7-ADCA , with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 7-ADCA . This report contains market size and forecasts of 7-ADCA in Asia Pacific, including the following market information:
We surveyed the 7-ADCA manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
• China
• India
• Japan
• South Korea
• Australia
• Thailand
• Indonesia
• High Purity Type
• Low Purity Type
• Cefalexin
• Cefradine
• Cefadroxil
• CSPC Pharmaceutical Group Limited
• Lupin Pharmaceuticals, Inc.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Shandong New Time Pharmaceutical Co., Ltd.
• NCPC
• Cipla
• Aurobindo Pharma
• Dr. Reddy
1.1 Product Overview and Scope of 7-ADCA
1.2.1 Asia Pacific Market Size YoY Growth Rate Analysis by Type: 2023 VS 2030
1.2.2 High Purity Type
1.2.3 Low Purity Type
1.3.1 Asia Pacific Market Size YoY Growth Rate Analysis by Application: 2023 VS 2030
1.3.2 Cefalexin
1.3.3 Cefradine
1.3.4 Cefadroxil
1.4 Asia Pacific Market Growth Prospects
1.4.1 Asia Pacific Revenue Estimates and Forecasts (2019-2030)
1.4.2 Asia Pacific Production Estimates and Forecasts (2019-2030)
2.1 Industry Trends
2.1.1 SWOT Analysis
2.1.2 PESTEL Analysis
2.1.3 Porter’s Five Forces Analysis
2.2 Potential Market and Growth Potential Analysis
3.1 Asia Pacific Production by Manufacturers (2019-2023)
3.2 Asia Pacific Revenue Market Share by Manufacturers (2019-2023)
3.3 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Asia Pacific Average Price by Manufacturers (2019-2023)
3.5 Manufacturers Production Sites, Area Served, Product Type
3.6 Market Competitive Situation and Trends
3.6.1 Market Concentration Rate
3.6.2 Asia Pacific 5 and 10 Largest Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4.1 Asia Pacific Production
4.1.1 Asia Pacific Production YoY Growth Rate (2019-2023)
4.1.2 Asia Pacific Production, Revenue, Price and Gross Margin (2019-2024)
5.1 Asia Pacific
5.1.1 Asia Pacific Consumption by Country
5.1.2 Asia Pacific Sales, Consumption, Export, Import (2019-2023)
5.1.1 China
5.2.2 India
5.3.3 Japan
5.4.4 South Korea
5.5.5 Australia
5.6.6 Thailand
5.7.7 Indonesia
6.1 Asia Pacific Production Market Share by Type (2019-2024)
6.2 Asia Pacific Revenue Market Share by Type (2019-2024)
6.3 Asia Pacific Price by Type (2019-2024)
7.1 Asia Pacific Production Market Share by Application (2019-2024)
7.2 Asia Pacific Revenue Market Share by Application (2019-2024)
7.3 Asia Pacific Price by Application (2019-2024)
8.1 CSPC Pharmaceutical Group Limited
8.1.1 CSPC Pharmaceutical Group Limited Corporation Information
8.1.2 CSPC Pharmaceutical Group Limited Product Portfolio
8.1.3 CSPC Pharmaceutical Group Limited Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.1.4 CSPC Pharmaceutical Group Limited Main Business and Markets Served
8.1.5 CSPC Pharmaceutical Group Limited Recent Developments/Updates
8.2 Lupin Pharmaceuticals, Inc.
8.2.1 Lupin Pharmaceuticals, Inc. Corporation Information
8.2.2 Lupin Pharmaceuticals, Inc. Product Portfolio
8.2.3 Lupin Pharmaceuticals, Inc. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.2.4 Lupin Pharmaceuticals, Inc. Main Business and Markets Served
8.2.5 Lupin Pharmaceuticals, Inc. Recent Developments/Updates
8.3 Zhejiang Huahai Pharmaceutical Co., Ltd.
8.3.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
8.3.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Product Portfolio
8.3.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.3.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business and Markets Served
8.3.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments/Updates
8.4 Shandong New Time Pharmaceutical Co., Ltd.
8.4.1 Shandong New Time Pharmaceutical Co., Ltd. Corporation Information
8.4.2 Shandong New Time Pharmaceutical Co., Ltd. Product Portfolio
8.4.3 Shandong New Time Pharmaceutical Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.4.4 Shandong New Time Pharmaceutical Co., Ltd. Main Business and Markets Served
8.4.5 Shandong New Time Pharmaceutical Co., Ltd. Recent Developments/Updates
8.5 NCPC
8.5.1 NCPC Corporation Information
8.5.2 NCPC Product Portfolio
8.5.3 NCPC Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.5.4 NCPC Main Business and Markets Served
8.5.5 NCPC Recent Developments/Updates
8.6 Cipla
8.6.1 Cipla Corporation Information
8.6.2 Cipla Product Portfolio
8.6.3 Cipla Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.6.4 Cipla Main Business and Markets Served
8.6.5 Cipla Recent Developments/Updates
8.7 Aurobindo Pharma
8.7.1 Aurobindo Pharma Corporation Information
8.7.2 Aurobindo Pharma Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.7.3 Aurobindo Pharma Main Business and Markets Served
8.7.4 Aurobindo Pharma Recent Developments/Updates
8.8 Dr. Reddy
Frequently Asked Questions ?
